AVALO THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
AVALO THERAPEUTICS, INC. (AVTX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$36.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$36.36M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$19.63M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$30.63M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$20.77M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$156.74M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$31.54M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2018 was -$41.71M, a 633.26% decline from fiscal 2017.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2017 was $7.82M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.36M 10-Q · filed 2026-08-06 | -$55.99M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$19.63M 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | -$30.63M 10-Q · filed 2025-11-06 | -$51.39M derived: sum of 2 quarters · filed 2026-08-06 | -$64.54M 10-Q · filed 2025-11-06 | -$73.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$20.77M 10-Q · filed 2026-08-06 | -$33.91M 10-Q · filed 2026-08-06 | -$42.62M derived: sum of 3 quarters · filed 2026-08-06 | -$73.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$13.15M 10-Q · filed 2026-05-13 | -$21.85M derived: sum of 2 quarters · filed 2026-05-13 | -$52.41M derived: sum of 3 quarters · filed 2026-05-13 | -$160.11M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$39.27M derived: sum of 2 quarters · filed 2026-03-23 | -$146.96M derived: sum of 3 quarters · filed 2026-03-23 | -$156.74M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$30.56M 10-Q · filed 2025-11-06 | -$138.25M derived: sum of 2 quarters · filed 2025-11-06 | -$148.04M 10-Q · filed 2025-11-06 | -$267.71M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$107.69M 10-Q · filed 2025-08-07 | -$134.87M 10-Q · filed 2025-08-07 | -$237.15M derived: sum of 3 quarters · filed 2025-08-07 | -$242.38M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$121.29M 10-Q · filed 2025-05-12 | -$129.46M derived: sum of 2 quarters · filed 2025-05-12 | -$134.69M derived: sum of 3 quarters · filed 2025-05-12 | -$142.88M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$13.40M derived: sum of 2 quarters · filed 2025-03-20 | -$21.59M derived: sum of 3 quarters · filed 2025-03-20 | -$31.54M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$5.23M 10-Q · filed 2024-11-07 | -$13.42M derived: sum of 2 quarters · filed 2024-11-07 | -$23.38M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$8.19M 10-Q · filed 2024-08-12 | -$18.15M 10-Q · filed 2024-08-12 | ||
| 2018-12-31 | -$7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$31.82M derived: sum of 2 quarters · filed 2019-03-18 | -$41.71M 10-K · filed 2019-03-18 | |
| 2018-09-30 | -$24.60M 10-Q · filed 2018-11-13 | -$34.49M 10-Q · filed 2018-11-13 | ||
| 2017-12-31 | -$1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $9.37M derived: sum of 2 quarters · filed 2019-03-18 | $7.82M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $11.23M 10-Q · filed 2018-11-13 | $9.68M 10-Q · filed 2018-11-13 | ||
| 2016-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$7.81M derived: sum of 2 quarters · filed 2018-04-02 | -$16.47M 10-K · filed 2018-04-02 | |
| 2016-09-30 | -$6.17M 10-Q · filed 2017-11-07 | -$14.83M 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | -$10.49M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |